` BYSI (Beyondspring Inc) vs S&P 500 Comparison - Alpha Spread

BYSI
vs
S&P 500

Over the past 12 months, BYSI has underperformed S&P 500, delivering a return of -37% compared to the S&P 500's 12% growth.

Stocks Performance
BYSI vs S&P 500

Loading

Performance Gap
BYSI vs S&P 500

Loading
BYSI
S&P 500
Difference

Performance By Year
BYSI vs S&P 500

Loading
BYSI
S&P 500
Add Stock

Competitors Performance
Beyondspring Inc vs Peers

S&P 500
BYSI
ABBV
AMGN
GILD
VRTX
Add Stock

Beyondspring Inc
Glance View

Market Cap
66.9m USD
Industry
Biotechnology

BeyondSpring, Inc. engages in the the development and commercialization of immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. The company is headquartered in New York City, New York and currently employs 103 full-time employees. The company went IPO on 2017-03-09. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).

BYSI Intrinsic Value
Not Available
Back to Top